The APEX-002-A01-03 randomized, double-blind, placebo-controlled phase 2b study plans to recruit patients across Canada to evaluate the efficacy, safety and tolerability of APEX-52, a microdose, orally administered synthetic psilocybin drug product in treating depression and anxiety among adults diagnosed with PTSD. VANCOUVER, BC, Jan. 19, 2023 /CNW/ – Apex Labs Ltd. (APEX or the Company)…
